Antibody-drug conjugates (ADCs) represent an innovative class of potent anti-cancer agents. They combine the specificity of a monoclonal antibody with the potency of a cytotoxic drug, enabling targeted killing of cancer cells with lower off-target effects. Over time, ADCs have evolved to high complexity and variability, posing increasing challenges in product characterization and quality control that must be addressed to advance their use in the clinic.The first ADC received accelerated…
Read More…
Source: https://www.labiotech.eu/partner/importance-adc-characterization/